Androgen blockade in prostate cancer in 2002: Major benefits on survival in localized disease

Molecular and Cellular Endocrinology

Volumn 198, Issue 1-2, 2002, Pages 77-87

  Labrie, Fernand ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

Androgen blockade; Antiandrogens; Brachytherapy; Combined androgen blockade; LHRH agonists; Monotherapy; Prostate cancer; Radiation therapy; Radical prostatectomy

Indexed keywords

ANDROGEN; ANTIANDROGEN; BICALUTAMIDE; FLUTAMIDE; GONADORELIN AGONIST; NILUTAMIDE; PROSTATE SPECIFIC ANTIGEN;

ADVANCED CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER LOCALIZATION; CANCER SURVIVAL; CASTRATION; CONFERENCE PAPER; DISEASE SEVERITY; DRUG EFFICACY; FOLLOW UP; HUMAN; INTERMETHOD COMPARISON; LONG TERM CARE; MONOTHERAPY; PRIORITY JOURNAL; PROSTATE CANCER; SURVIVAL RATE; SURVIVAL TIME;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANDROGENS; ANTINEOPLASTIC AGENTS, HORMONAL; COMBINED MODALITY THERAPY; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; PROSTATIC NEOPLASMS; QUEBEC; RANDOMIZED CONTROLLED TRIALS; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 0037203484     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0303-7207(02)00371-4     Document Type: Conference Paper

References (52)

1. Aus G., Hugosson J., Norlén L. Long-term survival and mortality in prostate cancer treated with noncurative intent. J. Urol. 154:1995;460-465.
2. Bangma C.H., Kranse R., Blijenberg B.G., Schroder F.H. The value of screening tests in the detection of prostate cancer. Part I: results of a retrospective evaluation of 1726 men. Urology. 46:1995;773-778.
3. Bennett C.L., Tosteson T.D., Schmitt B., Weinberg P.D., Ernstoff M.S., Ross S.D. Maximum androgen-blockade with medical or surgical castration in advanced prostate cancer: a meta-analysis of nine published randomized controlled trials and 4128 patients using Flutamide. Prostate Cancer Prostatic Dis. 2:1999;4-8.
4. Bolla M., Gonzalez D., Warde P., Dubois J.B., Mirimanoff R.O., Storme G., Bernier J., Kuten A., Sternberg C., Gil T., Collette L., Pierart M. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. New Engl. J. Med. 337:1997;295-300.
5. Brawer M.K., Crawford E.D., Labrie F., Mendoza-Valdez A., Miller P.D., Petrylak D.P. Advanced disease. Rev. Urol. 3:(Suppl. 2):2001;559.
6. Candas, B., Labrie, F., 2000. Unequal decrease of prostate cancer specific death rates through the Province of Quebec between 1991 and 1999. Fourteenth International Symposium J. Steroid Biochem. Mol. Biol., Québec, Canada, pp. 133, Abst. 86-P.
7. Candas B., Cusan L., Gomez J.-L., Diamond P., Suburu R.E., Lévesque J., Brousseau G., Bélanger A., Labrie F. Evaluation of prostatic specific antigen and digital rectal examination as screening tests for prostate cancer. Prostate. 45:2000;19-35.
8. Carlsson P., Hjertberg H., Jonsson B., Varenhorst E. The cost of prostatic cancer in a defined population. Scand. J. Urol. Nephrol. 23:1989;93-96.
9. Caubet J.F., Tosteson T.D., Dong E.W., Naylon E.M., Whiting G.W., Ernstoff M.S., Ross S.D. Maximum androgen blockade in advanced prostate cancer: a meta-analysis of published randomized controlled trials using nonsteroidal antiandrogens. Urology. 49:1997;71-78.
10. Crawford E.D., Eisenberger M.A., McLeod D.G., Spaulding J.T., Benson R., Dorr F.A., Blumenstein B.A., Davis M.A., Goodman P.J. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. New Engl. J. Med. 321:1989;419-424.
11. Denis L. EORTC 30853. Cancer. 71:1993;1050-1058.
12. Denis L., Carnelro de Moura J., Bono A., Sylvester R., Whelan P., Newling D., Depauw M. Goserelin acetate and flutamide vs bilateral orchiectomy: a phase III EORTC trial (30853). EORTC GU Group and EORTC Data Center. Urology. 42:1993;119-129.
13. Denis L.J., Keuppens F., Smith P.H., Whelan P., Carneiro de Moura J.L., Newling D., Bono A., Sylvester R. Maximal androgen blockade: final analysis of EORTC Phase III trial 30853. Eur. Urol. 33:1998;144-151.
14. Dijkman G.A., Janknegt R.A., Dereijke T.M., Debruyne F.M.J. Long-term efficacy and safety of nilutamide plus castration in advanced prostate-cancer, and the significance of early prostate specific antigen normalization. J. Urol. 158:1997;160-163.
15. Faure N., Labrie F., Lemay A., Bélanger A., Gourdeau Y., Laroche B., Robert G. Inhibition of serum androgen levels by chronic intranasal and subcutaneous administration of a potent luteinizing hormone-releasing hormone (GNRH) agonist in adult men. Fertil. Steril. 37:1982;416-424.
16. Granfors T., Modig H., Damber J.E., Tomic R. Combined orchiectomy and external radiotherapy versus radiotherapy alone for nonmetastatic prostate cancer with or without pelvic lymph node involvement: a prospective randomized study. J. Urol. 159:1998;2030-2034.
17. Hanks, G.E., Lu, J., Machtay, M., Venkatesan, V., Pinover, W., Byhardt, R., Rosenthal, S.A., 2000. RTOG Protocol 92-02: A Phase III trial of the use of long term androgen suppression following neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate. Thirtysixth Annual Meeting of the American Society of Clinical Oncology, New Orleans, LA, USA, pp. 1284.
18. Hugosson J., Aus G., Becker C., Carlsson S., Eriksson H., Lilja H., Lodding P., Tibblin G. Would prostate cancer detected by screening with prostate-specific antigen develop into clinical cancer if left undiagnosed? A comparison of two population-based studies in Sweden. BJU Int. 85:2000;1078-1084.
19. Janknegt R.A., Abbou C.C., Bartoletti R., Bernstein-Hahn L., Bracken B., Brisset J.M., Da Silva F.C., Chisholm G., Crawford E.D., Debruyne F.M.J., Dijkman G.D., Frick J., Goedhals L., Knönagel H., Venner P.M. Orchiectomy and Nilutamide or placebo as treatment of metastatic prostatic cancer in a multinational double-blind randomized trial. J. Urol. 149:1993;77-83.
20. Kolata G. Prostate cancer consensus hampered by lack of data. Science. 236:1987;1626-1627.
21. Labrie F. Intracrinology. Mol. Cell. Endocrinol. 78:1991;C113-C118.
22. Labrie F. Prostate cancer and combined androgen blockade at all stages of disease. Khayat D., Hortobagyi G.N. Progress in Anti-Cancer Chemotherapy. 2000;171-187 Springer, France, Berlin, Heidelberg.
23. Labrie F. Screening and hormonal therapy of localized prostate cancer show major benefits on survival. Cancer J. Sci. Am. 6:2000;S182-S187.
24. Labrie F., Crawford D. Anti-androgens in treatment of prostate cancer. Lancet. 346:1995;1030-1031.
25. Labrie F., Bélanger A., Cusan L., Séguin C., Pelletier G., Kelly P.A., Reeves J.J., Lefebvre F.A., Lemay A., Raynaud J.P. Antifertility effects of LHRH agonists in the male. J. Androl. 1:1980;209-228.
26. Labrie F., Dupont A., Bélanger A., Cusan L., Lacourciére Y., Monfette G., Laberge J.G., Emond J., Fazekas A.T., Raynaud J.P., Husson J.M. New hormonal therapy in prostatic carcinoma: combined treatment with an LHRH agonist and an antiandrogen. Clin. Invest. Med. 5:1982;267-275.
27. Labrie F., Dupont A., Bélanger A. Complete androgen blockade for the treatment of prostate cancer. de Vita V.T., Hellman S., Rosenberg S.A. Important Advances in Oncology. 1985;193-217 J.B. Lippincott, Philadelphia.
28. Labrie C., Bélanger A., Labrie F. Androgenic activity of dehydroepiandrosterone and androstenedione in the rat ventral prostate. Endocrinology. 123:1988;1412-1417.
29. Labrie F., Dupont A., Suburu R., Cusan L., Gomez J.L., Koutsilieris M., Diamond P., Emond J., Lemay M., Têtu B. Optimized strategy for detection of early stage, curable prostate cancer: role of prescreening with prostatic-specific antigen. Clin. Invest. Med. 16:1993;425-439.
30. Labrie F., Cusan L., Gomez J.L., Diamond P., Suburu R., Lemay M., Tetu B., Fradet Y., Candas B. Downstaging of early stage prostate cancer before radical prostatectomy: the first randomized trial of neoadjuvant combination therapy with Flutamide and a luteinizing hormone-releasing hormone agonist. Urology. 44:(6A):1994;29-37.
31. Labrie F., Bélanger A., Cusan L., Simard J., Luu-The V., Labrie C., Gomez J.L., Diamond P., Candas B. History of LHRH agonists and combination therapy in prostate cancer. Endocr. Related Cancer. 3:1996;243-278.
32. Labrie F., Candas B., Cusan L., Gomez J.L., Diamond P., Suburu R., Lemay M. Diagnosis of advanced or noncurable prostate cancer can be practically eliminated by prostate-specific antigen. Urology. 47:1996;212-217.
33. Labrie F., Cusan L., Gomez J.L., Diamond P., Bélanger A. Long-term neoadjuvant and adjuvant combined androgen blockade is needed for efficacy of treatment in localized prostate cancer. Mol. Urol. 1:1997;253-261.
34. Labrie F., Candas B., Dupont A., Cusan L., Gomez J.L., Suburu R.E., Diamond P., Lévesque J., Bélanger A. Screening decreases prostate cancer death: first analysis of the Quebec prospective randomized controlled trial. Prostate. 38:1999;83-91.
35. Labrie F., Cusan L., Gomez J.L., Belanger A., Candas B. Long-term combined androgen blockade alone for localized prostate cancer. Mol. Urol. 3:1999;217-225.
36. Laverdiere J., Gomez J.L., Cusan L., Suburu R., Diamond P., Lemay M., Candas B., Fortin A., Labrie F. Beneficial effect of combination therapy administered prior and following external beam radiation therapy in localized prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 37:1997;247-252.
37. Lee F., Torp-Pedersen S.T., Siders D.B., Littrup P.J., McLeary R.D. Transrectal ultrasound in the diagnosis and staging of prostatic carcinoma. Radiology. 170:1989;609-615.
38. Lodding P., Aus G., Bergdahl S., Frosing R., Lilja H., Pihl C.G., Hugosson J. Characteristics of screening detected prostate cancer in men 50 to 66 years old with 3 to 4 ng/ml. Prostate specific antigen. J. Urol. 159:1998;899-903.
39. Makinen T., Tammela T.L., Hakama M., Stenman U.H., Rannikko S., Aro J., Juusela H., Maattanen L., Auvinen A. Prostate cancer screening within a prostate specific antigen range of 3 to 3.9 ng/ml: a comparison of digital rectal examination and free prostate specific antigen as supplemental screening tests. J. Urol. 166:2001;1339-1342.
40. Messing E.M., Manola J., Sarosdy M., Wilding G., Crawford E.D., Trump D. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. New Engl. J. Med. 341:1999;1781-1788.
41. Middleton R.G., Thompson I.M., Austenfeld M.S., Cooner W.H., Correa R.J., Gibbons R.P., Miller H.C., Oesterling J.E., Resnick M.I., Smalley S.R., et al. Prostate cancer clinical guidelines panel summary report on the management of clinically localized prostate cancer. The American Urological Association. J. Urol. 154:1995;2144-2148.
42. Otnes B., Harvei S., Fossa S.D. The burden of prostate cancer from diagnosis until death. Br. J. Urol. 76:1995;587-594.
43. Peeling W.B. Phase III studies to compare goserelin (Zoladex) with orchiectomy and with diethylstilbestrol in treatment of prostatic carcinoma. Urology. 33:1989;45-52.
44. Pilepich M.V., Caplan R., Byhardt R.W., Lawton C.A., Gallagher M.J., Mesic J.B., Hanks G.E., Coughlin C.T., Porter A., Shipley W.U., Grignon D. Phase III trial of androgen suppression using Goserelin in unfavorable prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group protocol 85-31. J. Clin. Oncol. 15:1997;1013-1021.
45. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet. 355:2000;1491-1498.
46. Robinson M.R., Thomas B.S. Effect of hormone therapy on plasma testosterone levels in prostatic cancer. Br. Med. J. 4:1971;391-394.
47. Oks Herceptin label change. Food Drug Admin. 2705:2001;21.
48. Shröder F.H., Maas P.V.D., Beemsterboer P., Kruger A.B., Hoedemaeker R., Rietbergen J. Evaluation of the digital rectal examination as a screening test for prostate cancer. J. Natl. Cancer Inst. 90:1998;1817-1823.
49. Shröder F.H., Roobol-Bouts M., Vis A.N., Kwast T.V.D., Kranse R. Prostate-specific antigen-based early detection of prostate cancer-validation of screening without rectal examination. Urology. 57:2001;83-90.
50. Tolis G., Ackman D., Stellos A., Mehta A., Labrie F., Fazekas A.T.A., Comaru-Schally A.M., Schally A.V. Tumor growth inhibition in patients with prostatic carcinoma treated with LHRH agonists. Proc. Natl. Acad. Sci. 79:1982;1658-1662.
51. Treatment and survival of patients with cancer of the prostate. Surg. Gynecol. Obstet. 124:1967;1011-1017.
52. Wirth M., Tyrrell C., Wallace M., Delaere K.P., Sanchez-Chapado M., Ramon J., Hetherington J., Pina F., Heynes C.F., Borchers T.M., Morris T., Stone A. Bicalutamide (Casodex) 150 mg as immediate therapy in patients with localized or locally advanced prostate cancer significantly reduces the risk of disease progression. Urology. 58:2001;146-151.